| Primary |
| Meningitis Cryptococcal |
14.1% |
| Cryptococcosis |
11.9% |
| Antifungal Treatment |
6.7% |
| Langerhans' Cell Granulomatosis |
6.7% |
| Visceral Leishmaniasis |
6.7% |
| Acute Myeloid Leukaemia |
6.3% |
| Antifungal Prophylaxis |
4.1% |
| Aspergillosis |
4.1% |
| Fungal Infection |
4.1% |
| Paracoccidioides Infection |
4.1% |
| Bronchopulmonary Aspergillosis |
3.7% |
| Immunosuppression |
3.7% |
| Mucormycosis |
3.7% |
| Febrile Neutropenia |
3.3% |
| Hiv Infection |
3.3% |
| Zygomycosis |
3.3% |
| Infection |
3.0% |
| Candidiasis |
2.6% |
| Meningitis |
2.6% |
| Antiretroviral Therapy |
2.2% |
|
| Tachycardia |
11.9% |
| Renal Failure Acute |
11.0% |
| Drug Ineffective |
8.3% |
| Vomiting |
6.4% |
| Death |
5.5% |
| Rhabdomyolysis |
5.5% |
| Thrombocytopenia |
5.5% |
| Nephrogenic Diabetes Insipidus |
4.6% |
| Renal Failure |
4.6% |
| Renal Impairment |
4.6% |
| Visceral Leishmaniasis |
4.6% |
| Zygomycosis |
4.6% |
| Off Label Use |
3.7% |
| Hepatotoxicity |
2.8% |
| Hyponatraemia |
2.8% |
| Mucormycosis |
2.8% |
| Neutropenia |
2.8% |
| Overdose |
2.8% |
| Oxygen Saturation Decreased |
2.8% |
| Pyrexia |
2.8% |
|
| Secondary |
| Drug Use For Unknown Indication |
15.9% |
| Product Used For Unknown Indication |
14.9% |
| Aspergillosis |
8.4% |
| Bronchopulmonary Aspergillosis |
5.9% |
| Prophylaxis |
5.6% |
| Antifungal Prophylaxis |
5.4% |
| Hiv Infection |
5.2% |
| Pneumonia |
4.3% |
| Fungal Infection |
4.1% |
| Immunosuppression |
3.7% |
| Meningitis Cryptococcal |
3.6% |
| Acute Myeloid Leukaemia |
3.5% |
| Histoplasmosis |
3.4% |
| Extranodal Nk/t-cell Lymphoma, Nasal Type |
3.1% |
| Immunosuppressant Drug Therapy |
2.5% |
| Keratitis Fungal |
2.3% |
| Febrile Neutropenia |
2.3% |
| Fusarium Infection |
2.1% |
| Acute Lymphocytic Leukaemia |
2.0% |
| Infection Prophylaxis |
1.9% |
|
| Drug Ineffective |
12.6% |
| Pyrexia |
10.7% |
| Renal Impairment |
8.1% |
| Renal Failure Acute |
7.8% |
| Vomiting |
6.3% |
| Toxic Epidermal Necrolysis |
5.9% |
| Renal Failure |
5.6% |
| Sepsis |
4.8% |
| Thrombocytopenia |
4.4% |
| Weight Decreased |
4.1% |
| White Blood Cell Count Decreased |
3.7% |
| Death |
3.3% |
| Meningitis Cryptococcal |
3.3% |
| Multiple-drug Resistance |
3.3% |
| Bronchopulmonary Aspergillosis |
3.0% |
| Drug Resistance |
3.0% |
| Liver Disorder |
3.0% |
| Cytomegalovirus Infection |
2.6% |
| Aspergillosis |
2.2% |
| Hiccups |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
20.1% |
| Drug Use For Unknown Indication |
15.5% |
| Prophylaxis |
14.7% |
| Infection Prophylaxis |
6.2% |
| Pneumonia |
4.6% |
| Diffuse Large B-cell Lymphoma |
4.3% |
| Acute Myeloid Leukaemia |
3.8% |
| Aplastic Anaemia |
3.7% |
| Antifungal Prophylaxis |
3.3% |
| Prophylaxis Against Graft Versus Host Disease |
3.2% |
| Hypertension |
3.1% |
| Hiv Infection |
3.1% |
| Bone Marrow Conditioning Regimen |
2.7% |
| Antiviral Prophylaxis |
2.1% |
| Premedication |
1.8% |
| Systemic Candida |
1.7% |
| Acute Lymphocytic Leukaemia |
1.6% |
| Infection |
1.6% |
| Pyrexia |
1.5% |
| B-cell Lymphoma |
1.4% |
|
| Respiratory Failure |
13.4% |
| Sepsis |
11.6% |
| Pyrexia |
8.2% |
| Vomiting |
6.9% |
| White Blood Cell Count Decreased |
5.9% |
| Drug Ineffective |
4.7% |
| Febrile Neutropenia |
4.1% |
| Multi-organ Failure |
3.9% |
| Renal Failure |
3.9% |
| Septic Shock |
3.9% |
| Urinary Retention |
3.9% |
| Death |
3.8% |
| Stomatitis |
3.8% |
| Weight Decreased |
3.8% |
| Pneumonia |
3.6% |
| Thrombocytopenia |
3.4% |
| Pancytopenia |
3.3% |
| Staphylococcal Infection |
2.8% |
| Zygomycosis |
2.8% |
| Drug Resistance |
2.6% |
|
| Interacting |
| Coccidioidomycosis |
66.7% |
| Ill-defined Disorder |
16.7% |
| Product Used For Unknown Indication |
16.7% |
|
| Malaise |
25.0% |
| Nodal Rhythm |
25.0% |
| Renal Failure Acute |
25.0% |
| Renal Impairment |
25.0% |
|
